Zentalis Pharmaceuticals Inc’s market performance has been unstable in recent times. The company’s stock hit a 1-year high of $18.07 on 02/28/24 and a low of $2.66 for the same time frame on 10/31/24.
52-week price history of ZNTL Stock
Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. Zentalis Pharmaceuticals Inc’s current trading price is -83.12% away from its 52-week high, while its distance from the 52-week low is 14.66%. The stock’s price range during the 52-week period has remained between $2.66 and $18.07. In the Healthcare sector, the company’s shares saw a trading volume of around 1.2 million for the day, which was evidently lower than the average daily volume of 2.02 million over the past three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Market Capitalization and Financial Performance: An In-Depth Look
Zentalis Pharmaceuticals Inc (ZNTL) has experienced a quarterly decline of -2.87% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 190.95M and boasts a workforce of 168 employees.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.52, with a change in price of -1.15. Similarly, Zentalis Pharmaceuticals Inc recorded 1,683,068 in trading volume during the last 100 days, posting a change of -27.38%.
Examining ZNTL’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for ZNTL stands at 0.12. Similarly, the long-term debt-to-equity ratio is also 0.11.
ZNTL Stock Stochastic Average
Zentalis Pharmaceuticals Inc’s raw stochastic average for the past 50 days is presently 14.03%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 21.91%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 46.63% and 60.19%, respectively.
ZNTL Stock Price Performance Analysis
The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. The index has shown a price loss of -79.87% this year. Over the last six months, there has been a stronger performance of -74.13%. The price of ZNTL leaped by -2.87% during the last 30 days period. For the last 5-days stocks have slided -24.32%.
